NIH halts enrollment in trial for SIGA’s mpox antiviral after disappointing data

An­oth­er tri­al for SIGA Tech­nolo­gies’ mpox an­tivi­ral has failed, and all en­roll­ment has been stopped, the NIH’s Na­tion­al In­sti­tute of Al­ler­gy and In­fec­tious Dis­eases an­nounced …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.